PortalPublikationenValidation of a clinician questionnaire to assess reasons fo...

Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia.

Standard

Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia. / Matza, Louis S; Phillips, Glenn A; Revicki, Dennis A; Ascher-Svanum, Haya; Malley, Karen G; Palsgrove, Andrew C; Faries, Douglas E; Stauffer, Virginia; Kinon, Bruce J; George Awad, A; Keefe, Richard S E; Naber, Dieter.

in: PSYCHIAT RES, Jahrgang 200, Nr. 2-3, 2-3, 2012, S. 835-842.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Matza, LS, Phillips, GA, Revicki, DA, Ascher-Svanum, H, Malley, KG, Palsgrove, AC, Faries, DE, Stauffer, V, Kinon, BJ, George Awad, A, Keefe, RSE & Naber, D 2012, 'Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia.', PSYCHIAT RES, Jg. 200, Nr. 2-3, 2-3, S. 835-842. <http://www.ncbi.nlm.nih.gov/pubmed/22841345?dopt=Citation>

APA

Matza, L. S., Phillips, G. A., Revicki, D. A., Ascher-Svanum, H., Malley, K. G., Palsgrove, A. C., Faries, D. E., Stauffer, V., Kinon, B. J., George Awad, A., Keefe, R. S. E., & Naber, D. (2012). Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia. PSYCHIAT RES, 200(2-3), 835-842. [2-3]. http://www.ncbi.nlm.nih.gov/pubmed/22841345?dopt=Citation

Vancouver

Matza LS, Phillips GA, Revicki DA, Ascher-Svanum H, Malley KG, Palsgrove AC et al. Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia. PSYCHIAT RES. 2012;200(2-3):835-842. 2-3.

Bibtex

@article{4eab9b08da654a31bf0791033d5e6230,
title = "Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia.",
abstract = "The Reasons for Antipsychotic Discontinuation Questionnaire (RAD-Q) was designed to assess clinicians' perceptions of reasons for antipsychotic discontinuation or continuation. The current study examined psychometric properties of this instrument and patterns of antipsychotic discontinuation. The sample of 121 patients (81 discontinuation, 40 continuation) with schizophrenia or schizoaffective disorder was 66.9% male, with a mean age of 41.6 years. Treating clinicians reported a mean of 4.1 reasons for discontinuation and 7.5 reasons for continuation. RAD-Q domain scores were derived to quantify the impact of three factors on the decision to discontinue or continue: treatment benefits, adverse events, and distal reasons other than direct effects of the medication. Analysis of inter-rater reliability indicated an acceptable degree of agreement between clinicians (weighted Kappa for discontinuation scores=0.70-0.78). Correlations with symptom measures (Clinical Global Impression-Schizophrenia Scale (CGI-SCH), Positive and Negative Syndrome Scale (PANSS)) supported convergent validity of the benefits domain score (r=0.28-0.47; all p",
keywords = "Adult, Humans, Male, Female, Middle Aged, Quality of Life, Questionnaires, Treatment Outcome, Reproducibility of Results, Antipsychotic Agents/*therapeutic use, *Patient Satisfaction, Schizophrenia/*drug therapy, Health Care Surveys, Withholding Treatment/*statistics & numerical data, Adult, Humans, Male, Female, Middle Aged, Quality of Life, Questionnaires, Treatment Outcome, Reproducibility of Results, Antipsychotic Agents/*therapeutic use, *Patient Satisfaction, Schizophrenia/*drug therapy, Health Care Surveys, Withholding Treatment/*statistics & numerical data",
author = "Matza, {Louis S} and Phillips, {Glenn A} and Revicki, {Dennis A} and Haya Ascher-Svanum and Malley, {Karen G} and Palsgrove, {Andrew C} and Faries, {Douglas E} and Virginia Stauffer and Kinon, {Bruce J} and {George Awad}, A and Keefe, {Richard S E} and Dieter Naber",
year = "2012",
language = "English",
volume = "200",
pages = "835--842",
journal = "PSYCHIAT RES",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",
number = "2-3",

}

RIS

TY - JOUR

T1 - Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia.

AU - Matza, Louis S

AU - Phillips, Glenn A

AU - Revicki, Dennis A

AU - Ascher-Svanum, Haya

AU - Malley, Karen G

AU - Palsgrove, Andrew C

AU - Faries, Douglas E

AU - Stauffer, Virginia

AU - Kinon, Bruce J

AU - George Awad, A

AU - Keefe, Richard S E

AU - Naber, Dieter

PY - 2012

Y1 - 2012

N2 - The Reasons for Antipsychotic Discontinuation Questionnaire (RAD-Q) was designed to assess clinicians' perceptions of reasons for antipsychotic discontinuation or continuation. The current study examined psychometric properties of this instrument and patterns of antipsychotic discontinuation. The sample of 121 patients (81 discontinuation, 40 continuation) with schizophrenia or schizoaffective disorder was 66.9% male, with a mean age of 41.6 years. Treating clinicians reported a mean of 4.1 reasons for discontinuation and 7.5 reasons for continuation. RAD-Q domain scores were derived to quantify the impact of three factors on the decision to discontinue or continue: treatment benefits, adverse events, and distal reasons other than direct effects of the medication. Analysis of inter-rater reliability indicated an acceptable degree of agreement between clinicians (weighted Kappa for discontinuation scores=0.70-0.78). Correlations with symptom measures (Clinical Global Impression-Schizophrenia Scale (CGI-SCH), Positive and Negative Syndrome Scale (PANSS)) supported convergent validity of the benefits domain score (r=0.28-0.47; all p

AB - The Reasons for Antipsychotic Discontinuation Questionnaire (RAD-Q) was designed to assess clinicians' perceptions of reasons for antipsychotic discontinuation or continuation. The current study examined psychometric properties of this instrument and patterns of antipsychotic discontinuation. The sample of 121 patients (81 discontinuation, 40 continuation) with schizophrenia or schizoaffective disorder was 66.9% male, with a mean age of 41.6 years. Treating clinicians reported a mean of 4.1 reasons for discontinuation and 7.5 reasons for continuation. RAD-Q domain scores were derived to quantify the impact of three factors on the decision to discontinue or continue: treatment benefits, adverse events, and distal reasons other than direct effects of the medication. Analysis of inter-rater reliability indicated an acceptable degree of agreement between clinicians (weighted Kappa for discontinuation scores=0.70-0.78). Correlations with symptom measures (Clinical Global Impression-Schizophrenia Scale (CGI-SCH), Positive and Negative Syndrome Scale (PANSS)) supported convergent validity of the benefits domain score (r=0.28-0.47; all p

KW - Adult

KW - Humans

KW - Male

KW - Female

KW - Middle Aged

KW - Quality of Life

KW - Questionnaires

KW - Treatment Outcome

KW - Reproducibility of Results

KW - Antipsychotic Agents/therapeutic use

KW - Patient Satisfaction

KW - Schizophrenia/drug therapy

KW - Health Care Surveys

KW - Withholding Treatment/statistics & numerical data

KW - Adult

KW - Humans

KW - Male

KW - Female

KW - Middle Aged

KW - Quality of Life

KW - Questionnaires

KW - Treatment Outcome

KW - Reproducibility of Results

KW - Antipsychotic Agents/therapeutic use

KW - Patient Satisfaction

KW - Schizophrenia/drug therapy

KW - Health Care Surveys

KW - Withholding Treatment/statistics & numerical data

M3 - SCORING: Journal article

VL - 200

SP - 835

EP - 842

JO - PSYCHIAT RES

JF - PSYCHIAT RES

SN - 0165-1781

IS - 2-3

M1 - 2-3

ER -